Press Release

December 01, 2021
1 min read

Mirvetuximab soravtansine active in previously treated ovarian cancer


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Mirvetuximab soravtansine induced confirmed objective response in about one-third of women with folate receptor alpha-high platinum-resistant ovarian cancer who previously received bevacizumab, according to the agent’s manufacturer.

Mirvetuximab soravtansine (IMGN853, ImmunoGen) is a first-in-class antibody-drug conjugate that comprises a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a tubulin-targeting agent.

The single-arm SORAYA study assessed mirvetuximab soravtansine monotherapy for 106 women with folate receptor alpha-high, platinum-resistant ovarian cancer.

Study participants had received a median three prior lines of therapy (range, 1-4). All patients had received prior bevacizumab (Avastin, Genentech) and 48% received a poly(ADP-ribose) polymerase (PARP) inhibitor.

Median follow-up was 8.1 months.

The study met its primary endpoint, with company-issued topline results showing a confirmed objective response rate of 32.4% (95% CI, 23.6-42.2) per investigator assessment and 31.6% (95% CI, 22.4-41.9) by blinded independent central review. Researchers reported responses regardless of prior PARP inhibitor therapy or number of prior lines of therapy.

Median duration of response, a key secondary endpoint, was 5.9 months (95% CI, 5.6-7.7).

Treatment-related adverse events led to dose reductions for 19% of study participants, dose delays for 32% and treatment discontinuation for 7%.

The most common treatment-related adverse events included blurred vision (all grade, 41%; grade 3 or higher, 6% ), keratopathy (all grade, 35%; grade 3 or higher, 9%) and nausea (all grade, 29%; grade 3 or higher, 0%).

Robert Coleman
Robert Coleman

"Despite advances in the platinum-sensitive setting, most patients with ovarian cancer eventually develop platinum-resistant disease, for which there are limited treatment options, especially for those patients who have previously received bevacizumab," Robert Coleman, MD, chief scientific officer of US Oncology Research and co-principal investigator of the SORAYA study, said in an ImmunoGen-issued press release. “Data from SORAYA have the potential to redefine the standard of care for patients with [folate receptor alpha-high] platinum-resistant ovarian cancer, as this trial has demonstrated that mirvetuximab delivers clinically meaningful benefit in this setting, with significant and durable responses and a favorable tolerability profile.”